KRAS and colonic neoplasm: For example, Ki-67 and p53 have potential prognostic value in Dukes’ B and C colon cancer (Allegra et al., 2003), KRAS and BRAF have potential prognostic value in stage II and III resected colon cancer (Roth et al., 2010), the BRAF V600E mutation has been shown to be an independent prognostic factor for survival in stage II and stage III colon cancer patients (Farina-Sarasqueta et al., 2010), and SNORA42 may be a prognostic biomarker in CRC (Okugawa et al., 2017).